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Abstract
Ribonucleic acid interference (RNAi) based on microRNA (miRNA) context may provide an efficient and safe therapeutic
knockdown effect and can be driven by ribonucleic acid polymerase II (RNAP II). In this study, we designed and synthesized
miR155-based artificial miRNAs against heparanase (HPSE) constructed with BLOCK-iT
TM Pol II miR RNAi Expression Vector
Kit. The expression levels of HPSE declined significantly in both the mRNA and protein levels in HPSE-miRNA transfected
melanoma cells that exhibited reduction of adhesion, migration, and invasion ability in vitro and in vivo. We also observed
that HPSE miRNA could inhibit the expressions of chemokines of interleukin-8 (IL8) and chemokine (C-X-C motif) ligand 1
(CXCL1), at both the transcriptional and translational levels. Further study on its probable mechanism declared that down-
regulation of IL8 and CXCL1 by HPSE-miRNA may be correlated with reduced growth-factor simulated mitogen-activated
kinase (MAPK) phosphorylation including p38 MAPK, c-Jun N-terminal kinase (JNK) and extracellular-signal-regulated kinase
(ERK) 1 and 2, which could be rescued by miRNA incompatible mutated HPSE cDNA. In conclusion, we demonstrated that
artificial miRNAs against HPSE might serve as an alterative mean of therapy to low HPSE expression and to block the
adhesion, invasion, and metastasis of melanoma cells. Furthermore, miRNA-based RNAi was also a powerful tool for gene
function study.
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Introduction
Malignant melanoma is one of the most aggressive and fastest
increasing cancers with a high mortality and a poor prognosis [1].
Metastatic melanoma is difficult to treat with current therapies.
Therefore, it is of great significance to improve our understanding
of the complex molecular mechanisms of its invasive and
metastatic potential, and to further develop therapeutic modalities
for ideal targets to improve the survival rates of melanoma
patients.
HPSE is an endo-b-glucuronidase that can cleave heparan
sulfate proteoglycans (HPSG) within the extracellular matrix
(ECM), basement membrane (BM) or on the cellular surface,
facilitating metastasis by enhancing cell invasion, migration,
intravasation and extravasation [2]. Elevated expression of HPSE
in tumor cells dramatically enhances their growth, angiogenesis,
and metastasis to bone or brain [3–4]. PI-88, a potent HPSE
inhibitor, has shown antitumor activity in vitro and in vivo by
inhibiting vascular endothelial growth factor and fibroblast growth
factor, directly or indirectly, as well as stimulating the release of
tissue factor pathway inhibitors [5]. Promising results from Phase
I/II trials are being seen with PI-88 in a variety of tumor types.
However, the development of antibody-induced thrombocytope-
nia or neutropenia has limited the use of PI-88 in some patients
[5–6]. Therefore, there is still an unmet need for identifying and
developing a novel therapy to prevent the progression of tumors
without sacrificing patient quality of life.
RNAi is an attractive technology for the knockdown of specific
genes and is being developed as a therapeutic modality [7]. To
date, most expression-based RNAi strategies have utilized small
interfering RNA (siRNA) or short hairpin RNA (shRNA). The use
of siRNA (diced siRNA or synthetic siRNA) for RNAi analysis in
mammalian cells is limited by their transient nature and the lack of
an efficient delivery system in vivo [8,9]. The use of shRNA
requires the screening of a large number of sequences to identify
active sequences, and the use of Pol III promoters limits
applications such as tissue-specific expression [10,11]. miRNAs,
which endogenously express small ssRNA sequences of ,22
nucleotides, can naturally direct gene silencing through compo-
nents shared with the RNAi pathway [12]. Recently, it was
reported that using the endogenous processing machinery,
optimized shRNA constructs based on miRNAs may provide
more efficient and safer therapeutic RNAi expression [13–15].
Furthermore, such a shRNA embedded in a miRNA scaffold can
be driven by RNA Pol II [16], which makes tissue-specific RNAi
possible [17,18]. In this study, we constructed miR155-based
artificial miRNAs against HPSE with the BLOCK-iT
TM Pol II
miR RNAi Expression Vector Kit to investigate their effect on
HPSE down-modulation and other functions in vitro and in vivo,
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5with the aim of exploring an efficient and safe approach for
melanoma treatment.
Materials and Methods
Design and Synthesis of miR-155-based HPSE miRNA and
the Construction of Vectors
Pre-miRNA sequences for HPSE (NM_006665.3) were de-
signed by Invitrogen’s RNAi Designer (sequences were shown in
Figure 1A). The synthesized complementary DNA oligos (Ta-
KaRa Biotechnology Co. Ltd., Dalian, China) were annealed to
generate a double-stranded oligo and cloned into the linearized
pcDNA
TM 6.2-GW/EmGFP-miR vector (Invitrogen Corp.,
Carlsbad, CA, USA) using T4 DNA ligase (Figure 1B and C).
The Neg-miRNA control plasmid was included in the Block-
iT
TM-Pol II miR RNAi Expression Vector Kit (sequences were
shown in Figure 1A). All of the vectors were transformed into One
ShotH TOP10 Chemically Competent E. coli (Invitrogen Corp.),
and the colonies containing spectinomycin-resistant transformants
were analyzed for the desired expression clones. The recombinant
vectors were purified with a purification kit (Qiagen Inc., Valencia,
CA, USA) and confirmed by sequencing (TaKaRa).
Cell Culture and Stable Transfection
The human malignant melanoma cell line A375 was purchased
from the Shanghai Institute of Cell Biology (Shanghai, China) and
routinely maintained in Dulbecco’s modified Eagle’s medium
(DMEM) (Hyclone Laboratories, Inc., Logan, UT, USA) supple-
mented with 10% fetal bovine serum and 20 mmol/L of HEPES
(4-(2-hydroxyethyl)-1-piperazineethanesulfonic acid) in a 5% CO2
incubator at 37uC. The vectors with HPSE-miRNA1, HPSE-
miRNA2, HPSE-miRNA3 (targeting different sequences of HPSE
as shown in Figure 1A) or the Neg-miRNA were transfected into
A375 cells using Attractene Transfection Reagent (Qiagen Inc.)
according to the manufacturer’s protocol. For effective screening
of RNAi sequences targeting HPSE by quantitative real-time
polymerase chain reaction (PCR) and western blotting, the cells
were transiently transfected with each miRNA for 48 hours, when
the percentage of fluorescent cells was more than 80%. For further
study, the aforementioned transfectants were selected by fresh
DMEM medium containing 12.5 mg/mL blasticidin (Invitrogen
Corp.) every 3 to 4 days until blasticidin-resistant colonies could be
identified. To confirm the effect of the HPSE-miRNA on other
tumor cells with a high invasive ability, it was also transfected into
cervical carcinoma HeLa cells maintained in Roswell Park
Memorial Institute 1640 medium (Hyclone, Inc.).
Quantitative Real-time PCR
Total RNA was isolated from cells of different groups of
parental cells, which were transfected with Neg-miRNA, HPSE-
miRNA1, HPSE-miRNA2 or HPSE-miRNA3, using RNAiso
TM
PLUS (TaKaRa), following the manufacturer’s protocol. The
reactions were carried out in a 20 mL reaction volume containing
10 mLo f26SYBRH Premix Ex Taq
TM and 0.4 mLo f5 06ROX
reference dye (TaKaRa). Primers for HPSE, IL8, CXCL1, as well as
the internal control b-actin, were synthesized by the TaKaRa
Company as follows: HPSE-forward, 59-GAATGGACG-
GACTGCTAC -39, HPSE-reverse, 59-CCAAAGAA-
TACTTGCCTCA-39; IL8-forward, 59-ACACTG CGCCAACA-
CAGAAATTA-39, IL8-reverse, 59-
TTTGCTTGAAGTTTCACTGGCA TC-39; CXCL1-forward,
59-GAACATCCAAAGTGTGAACGTGAAG-39; CXCL1-re-
verse, 59-TTCAGGAACAGCCACCAGTGAG-39; b-actin-for-
ward, 59-GG CGGCACCACCATGTACCCT-39, b-actin-reverse,
59-AGGGGCCGGACTCGTCA TACT-39. The DCt data were
collected automatically. 2DDCt was calculated by 2DDCt=aver-
age DCt of the negative control group 2DCt of the treated group.
The relative expression for a target gene was calculated using
2
2DDCt. All experiments were repeated three times.
Western Blotting Analysis
Cells from different groups were harvested, lysed and subjected
to western blotting with the antibodies for the target genes as
described previously [19]. Antibodies to HPSE, anti-phospho-p38
MAPK (Thr180/Tyr182), anti-p38 MAPK, anti-phospho -JNK
(Thr183/Tyr185), anti-JNK, anti-phospho-ERK1/2 (Thr202/
Tyr204) and anti-ERK1/2 were obtained from AbcamH Biotech-
nology plc (San Francisco, CA, USA). Following 3 washes with
TBS/T buffer, the membranes were incubated with horseradish
peroxidase-conjugated anti-rabbit IgG for 1 hour at room
temperature. EZ-ECL (Biological Industries Israel Beit-Haemek
Ltd., Kibbutz Beit-Haemek, Israel) was subsequently used for
visualization of the bands. The membranes were stripped and
probed with the glyceraldehyde-3-phosphate dehydrogenase
(GAPDH) monoclonal antibody (KangChen Bio-tech Inc.,
Shanghai, China), which served as the internal control. All
experiments were repeated three times.
In vitro Cellular Viability and Proliferation Assay
Parental cells and cells stably transfected with Neg-miRNA,
HPSE-miRNA1, or HPSE-miRNA2 were seeded in 96-well plates
at a density of 5610
3 cells per well. Each group was repeated for 5
6 3 wells. After subculturing for 1, 24, and 48 hours, 20 mLo f
MTT (3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bro-
mide, 5 mg/mL) (Sigma-Aldrich Co. LLC, St Louis, MD, USA)
was added to each well, and the plates were incubated for an
additional 4 hours at 37uC. The MTT solution in the medium was
then aspirated, and 150 mL of dimethyl sulfoxide (Sigma-Aldrich
Co. LLC) was added before measurement of the absorbance at
570 nm. Cellular viability was evaluated by the A570 value. In
addition, we counted the cells number of each group after 24, 48,
72, and 96 hours of culture in replicated 6-well plates, at an initial
density of 1610
5 cells per well.
Annexin-V-fluorescein Isothiocyanate/Propidium Iodide
(Annexin-V-FITC/PI) Affinity Assay
Parental cells and cells that were stably transfected with Neg-
miRNA, HPSE-miRNA1, or HPSE-miRNA2 were collected and
re-suspended at 2610
6 cells/mL in Annexin-V binding buffer.
Each experiment was performed in triplicate. The supernatant
(100 mL/tube) was incubated with 5 mL of Annexin-V-FITC
(Biosource, Carmarillo, CA, USA) and 5 mL of propidium iodide
(Sigma-Aldrich) for 15 min at room temperature in the dark,
followed by cytometric analysis (Becton, Dickinson and Company,
Franklin, NJ, USA) within 1our of staining.
Cellular Adhesion Assay
Each well of the 96-well plates was coated with Matrigel (1:3
dilution ratio, BD) and bull serum albumin (2%, 20 mL), and dried
in a Superclean Bench. Parental cells and cells stably transfected
with Neg-miRNA, HPSE-miRNA1, or HPSE-miRNA2 were
collected and seeded in the prepared 96-well plates at a
concentration of 1 6 10
4 per well. Each experiment was
performed in quadruplicate. Cells that did not adhere to the
Matrigel were washed off by phosphate-buffered saline after a 1
hour of incubation at 37uC. The cellular adhesion ability was
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PLoS ONE | www.plosone.org 2 June 2012 | Volume 7 | Issue 6 | e38659Figure 1. Construction of of miR-155-based HPSE miRNAs and their impact on HPSE expression levels in A375 cells. A375 cells were
transfected with HPSE-miRNAs or Neg-miRNA for 48 hours. (A) The sequences and predicted secondary structures of three designed pre-miRNAs
targeting HPSE (HPSE-miRNA1, HPSE-miRNA2, and HPSE-miRNA3) and a negative control miRNA (Neg-miRNA), and the precise regions of the HPSE
mRNA that they targeted. (B) Pre-miRNA double-stranded oligo inserted into the miRNA expression vector-pcDNA6.2-GW/EmGFP-miR. (C) Schematic
representation of the process of ligation and transformation. (D) Inhibitory effects of HPSE miRNAs on HPSE protein expression. Representative blots
are shown from three independent experiments with identical results. The expressions of HPSE protein in A375 cells transfected with HPSE miRNAs
were obviously down-regulated obviously compared to the parental cells and the Neg-miRNA group. (E) Inhibitory effects of HPSE miRNAs on HPSE
mRNA expression. Calculation of the respective HPSE mRNA expression in each group was relative to the Neg-miRNA group (%). Quantitative real-
time PCR results showed that the expression of HPSE mRNA in A375 cells transfected with HPSE miRNAs were down-regulated compared to the
parental cells or the Neg-miRNA transfected cells. (
{P,0.05, compared with the parental cells; *P,0.05, compared with the Neg-miRNA transfected
cells).
doi:10.1371/journal.pone.0038659.g001
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assay.
Transwell Migration Assay and Matrigel Invasion Assay
Cells (2610
5/mL) from each group (100 mL) were re-suspended
in serum-free DMEM and seeded in the top chambers of non-
coated chambers (24-well insert; 8 mm pore size; Corning Costar
Corp., Cambridge, MA, USA). The chambers were then placed
into 24-well plates, and the lower chambers were filled with
0.5 mL of DMEM medium containing 10% fetal bovine serum as
a chemoattractant. After subculturing for 24 hours, the cells on the
upper surface of the membrane were removed using cotton tips.
The cells that migrated to the lower surface were fixed in 10%
formalin at room temperature for 30 minutes and stained with
hematoxylin and eosin (H&E). The cellular migration ability was
determined by counting the H&E-stained cells under the light
microscopy with a magnification of 1006. The ability of the cells
to invade through a Matrigel-coated filter was also measured in
transwell chambers, in addition that Matrigel (1:3 dilution, BD), a
reconstituted basement membrane containing HSPG, was added
to the bottom of each transwell chamber.
Gene Microarray Analysis
Total RNA were extracted from A375 cells stably transfected
with Neg-miRNA, HPSE-miRNA1, and HPSE-miRNA2. The
RNA samples were delivered to the LC Company (Hangzhou,
China) and analyzed by the Human Whole Genome OneArrayH
v5 (Phalanx Biotech Group, Taiwan, China) for gene microarray
analysis. The array contains 30,275 DNA oligonucleotide probes,
29,178 human genome probes, and 1,088 experimental control
probes formed as 60-mer sense-strand DNA elements. Four
hybridizations for each group were performed, with two biological
and two technical replicates. Briefly, the signal intensity of each
spot was loaded into the Rosetta Resolver SystemH (Rosetta
Biosoftware, Cambridge, MA, USA) for data analysis. The
technical repeat data were tested by Pearson’s correlation
coefficient calculation to check the reproducibility (R.0.95).
Normalized spot intensities were transformed to gene expression
log2 ratios between the control and treatment groups. The spots
with a log2 ratio $1 or log2 ratio #2 1 and P,0.05 were tested
for further analysis. Furthermore, a gene-set enrichment analysis
(GSEA, http://www.broadinstitute.org/gsea) was performed to
detect pathways that are significant. All data are MIAME
compliant, and the raw data have been deposited in a MIAME-
compliant database (accession number E-MEXP-3443).
ELISA Assay
Parental cells and cells stably transfected with Neg-miRNA,
HPSE-miRNA1, or HPSE-miRNA2 were incubated for 48 hours,
and the medium was collected and used for an enzyme-linked
immunosorbent assay (ELISA). IL8 and CXCL1 ELISAs were
performed according to the manufacturer’s instructions with the
ELISA kit (R&D SystemsH Inc., Minneapolis, MN, USA).
In vivo Assays for Tumor Metastasis
All animal protocols were approved by the Animal Care and
Use Committee of the Zhejiang University of Traditional Chinese
Medicine (Hangzhou, China). BALB/c-nu mice (4–5 weeks old)
were bred in laminar-flow cabinets and kept at a constant
humidity and temperature (25–28uC). Parental cells and cells
transfected stably with Neg-miRNA and HPSE-miRNA2 (200 mL,
1610
7/mL) were injected into the tail vain of nude mice (3 in each
group). The mice were weighed once a week and sacrificed 6
weeks later, at which time, the lungs and livers were removed.
Consecutive sections were made for every tissue block of the lungs
or livers and stained with H&E. The incidence of lung or liver
metastasis was calculated and evaluated independently by two
pathologists. Furthermore, the metastases were classified into
grade I-IV, according to the number of A375 cells in the
metastatic lesion [20].
Multisite-directed Mutagenesis for HPSE miRNA Rescue
Experiment
We performed the multisite-directed mutagenesis test to
corroborate the specificity of the phenotypic changes associated
with the HPSE miRNA. The pcDNA3.1-HPSE plasmid contain-
ing the full length human cDNA was kindly provided by Dr. Israel
Vlodavsky (Technion, Haifa, Israel). Primers for multisite muta-
genesis were designed and synthesized by Invitrogen Corp. as
follows: forward, 59-CTATCCGACACCTTT GCAGCCG-
GATTCATGTGGCTGGATAAATT-39; reverse, 59-AATT-
TATCCAGCC ACATGAATCCGGCTGCAAAGGTGTCG-
GATAG-39, in order; to introduce three nucleotide substitutions
within the HPSE-miRNA2 hybridizing sequence (59-
CCTTTGCAGCTGGCTTTATGT-39), while retaining the ami-
no acid identity of the wild-type protein. A detailed procedure of
the mutagenesis reaction was included in the Figure S1. DNA
from five colonies was isolated using a purification kit (Qiagen) and
sequenced (Invitrogen Corp.) to verify the presence of the designed
mutations. Original and mutant HPSE cDNAs were transfected
into cells that stably expressed Neg-miRNA, HPSE-miRNA1 and
HPSE-miRNA2. Total RNA, cell lysates and supernatants were
harvested at 48 hours after transfection for further analysis.
Statistical Analysis
The SAS software was used for statistical analysis. The results
were expressed as the mean6standard deviation. One-way
analysis of variance followed by the Dunnett-t and SNK-q tests
were used to assess significant differences among the groups.
P,0.05 was considered to be statistically significant. The results
were representative of at least three independent experiments with
reproducible results.
Results
Artificial HPSE miRNAs were Successfully Constructed,
which Down-regulated HPSE Expression in Melanoma
Cells
Three pcDNA6.2-GW/EmGFP-miR-based miRNA expression
plasmids with the pre-miRNA sequences of human HPSE mRNA,
termed HPSE-miRNA1, HPSE-miRNA2 and HPSE-miRNA3,
were constructed (Figure 1A). The positive plasmids were cloned,
sequenced, confirmed (Figure S2), and transfected into A375 cells,
which expressed high levels of HPSE [3,19]. Compared to the
parental cells and the negative control (Neg-miRNA), the cells
transfected with HPSE miRNAs for 48 hours demonstrated a
significantly decreased expression of the HPSE protein, especially
in the group of HPSE-miRNA1 and HPSE-miRNA2 groups
(Figure 1D). Consistent with the western blotting results, all of the
three HPSE miRNAs inhibited the expression of HPSE mRNA,
especially the HPSE-miRNA1 and HPSE-miRNA2 (69.76% and
60.31%, respectively, P,0.05, Figure 1E). Thus, the A375 cells
stably transfected with HPSE-miRNA1, HPSE-miRNA2 and
Neg-miRNA were selected with 12.5 mg/mL blasticidin and were
used for further studies. Furthermore, HPSE-miRNA1 and Neg-
miRNA were also transfected into HeLa cells, which also highly
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expression of HPSE (Figure S3A and B).
HPSE miRNAs Attenuated Cellular Viability and
Proliferation, but did not Induce Apoptosis of Melanoma
Cells in vitro
The flow cytometry results showed that the percentages of
apoptotic cells in both HPSE-miRNA groups did not differ from
the parental cells or the Neg-miRNA group (P.0.05, Figure 2A
and B). However, we found that cells transfected stably with HPSE
miRNA had reduced viability when compared to either control
group at 24 and 48 hours. The A570 value of each group detected
by MTT assay at 1 hour showed no differences (P.0.05). When
incubated for 24 or 48 hours, the A570 value of HPSE-miRNA1
and HPSE-miRNA2 was 0.78760.011, 0.76760.053 (24 hours)
and 1.05660.040, 1.24960.052 (48 hours), respectively, signifi-
cantly lower than both control groups (P,0.01) (Figure 2C). In
addition, similar results were found in the cellular proliferation
assay by counting cells number. Both HPSE-miRNA1 and HPSE-
miRNA2 were found to inhibit cellular proliferation of A375 cells
at 48, 72 and 96 hours, compared to the parental cells or Neg-
miRNA cells (P,0.05). At the 24 hour time point, however, the
cells number did not differ significantly amongst the groups
(P.0.05).
HPSE miRNAs Abolished the Adhesion, Migration, and
Invasion of Melanoma Cells in vitro
Adhesion to Matrigel was evaluated by MTT assay at the
indicated time point. The A570 value in both control groups
(0.91660.087 and 0.91660.142) differed significantly compared
to HPSE-miRNA1 (0.39860.022) and HPSE-miRNA2 transfect-
ed A375 cells (0.41660.068) (P,0.001, Figure 2E). Furthermore,
the number of A375 cells transfected with HPSE-miRNA1 or
HPSE-miRNA2 that migrated to the lower surface of the transwell
chambers and invaded through Matrigel at 24 hours was
significantly lower than that of the A375 cells in the control
groups (P,0.001, Figure 3F, G and H). In addition, HPSE-
miRNA1 could also attenuate the adhesion, migration, and
invasion ability of HeLa cells (Figure S3C, D, E and F).
Gene Expression Changes in HPSE miRNA Transfected
A375 Cells Detected by gene Microarray Assay
We analyzed and compared genes between the Neg-miRNA
transfected A375 cells and HPSE-miRNA1 or HPSE-miRNA2
transfected A375 cells by gene microarray analysis using
OneArray
TM slides. A total of 406 (HPSE-miRNA1 transfected)
and 680 (HPSE-miRNA2 transfected) genes were up or down-
regulated $2 fold (P,0.05), compared with the Neg-miRNA
transfected group (Figure S4A). Amongst these differentially
expressed genes, 205 genes were overlapping which indicated
that they are a result of HPSE knockdown, rather than
consequences of off-target effects of RNAi. The 205 overlapping
genes were analyzed for functional annotation by DAVID (http://
david.abcc.ncifcrf.gov/) and were found to be involved in growth-
factor binding, negative regulation of signal-transduction, immune
response, etc., as well as wound response, extracellular region
localization, heparin binding, inflammatory response, and regula-
tion of cell migration (Figure S4B). Furthermore, chemokines (e.g.,
IL8, CXCL1, CCL2 and CCL11) were found to be down-regulated
in both HPSE miRNA groups (Figure 3A). Additionally
chemokines were confirmed to be differentially expressed by
gene-set enrich analysis in HPSE miRNA groups compared with
the Neg-miRNA group (P,0.05, Figure 3B), which indicated that
HPSE may play a role in the production of chemokines.
Furthermore, we detected mRNA and protein expression of IL8
or CXCL1 by quantitative real-time PCR and ELISA assay. The
data demonstrated that the mRNA and protein levels of IL8 and
CXCL1 was decreased remarkably, compared to the parental cells
and the Neg-miRNA group (P,0.01, Figure 3C).
HPSE miRNAs Inhibited the Expression of IL8 and CXCL1,
in Part, by Attenuation of MAPK Phosphorylation
To verify whether the IL8/CXCL1/MAPK pathway was
blocked due to the lack of HPSE expression with artificial HPSE
miRNA, we performed western blotting for the phosphorylation of
MAPK, including p38 MAPK, JNK and ERK1/2. The levels of
p38 MAPK, JNK and ERK phosphorylation were reduced in
HPSE-miRNA1 and HPSE-miRNA2 transfected cells as com-
pared to Neg-miRNA transefected cells and the parental cells
(Figure 3D). These results suggested an involvement of HPSE-
mediated signaling on the expression of chemokines in melanoma
cells.
HPSE miRNA Suppressed Lung Metastasis of A375 Cells
At the start of the in vivo experiments, the weights of mice were
not different amongst the groups (P.0.05). One days 21, 28, 35
and 42 after the inoculation of tumor cells, the weights of the mice
in the HPSE-miRNA2 group were higher than both control
groups (P,0.05, Figure 4A and B). Unexpectedly, in our
experiments, there was no metastasis in the liver, another
vulnerable metastatic site of melanoma (data not shown). At the
end of the six weeks, the number of lung metastatic lesions in the
HPSE-miRNA2 group (2.33361.155) was much less than that in
the control groups (10.66762.216 and 11.00064.000) (P,0.05,
Figure 4C and D). Furthermore, the lung metastases in HPSE-
miRNA2 group were grade I (#20 cells) or grade II (20–50 cells),
while those in the negative control group or mock group were
grade III (50–100 cells) or grade IV (.100 cells) (Figure 4C).
Demonstration of the Specificity of HPSE-miRNA2
RNA interference rescue was used [22] to normalize artificial
miRNA-induced depletion of HPSE. We used multisite-directed
mutagenesis and introduced three nucleotide substitutions within
the HPSE-miRNA2 hybridizing sequence, while retaining the
amino acid identity of the wild-type protein (Figure 5A). As
shown in Figure 5B and C, introduction of the mutated HPSE
cDNA in HPSE-miRNA2 stably transfected cells not only
rescued the miRNA-induced HPSE inhibition but also increased
HPSE mRNA levels (P,0.0001), similar to those of Neg-miRNA
cells transfected with wild type or mutant HPSE cDNA (P.0.05).
Furthermore, the transfection of cDNA-mut for miRNA rescue
also increased IL8 and CXCL1 mRNA levels (P,0.01), indicating
HPSE could regulate IL8 and CXCL1 at the level of transcrip-
tion, or prior to translation. With respect to a regulatory
mechanism, HPSE-induced phosphorylation of MAPKs was also
restored in cells of the HPSE-miRNA2 group transfected with
mutant HPSE cDNA, but not with the wild type HPSE cDNA
(Figure 5E). However, in the HPSE-miRNA1 stably transfected
cells, neither the original HPSE cDNA nor the mutant HPSE
cDNA could restore the expression of HPSE, and subsequently,
to rescue the levels IL8 or CXCL1, and phosphorylation of
MAPKs (Figure 5B–E).
Discussion
Tumor invasion and metastasis is a multistep process that
promotes the spread of the cancer from primary sites to distant
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PLoS ONE | www.plosone.org 5 June 2012 | Volume 7 | Issue 6 | e38659Figure 2. Effects of HPSE miRNAs on A375 cells in vitro. A375 cells transfected stably with HPSE-miRNA1, HPSE-miRNA2 or Neg-miRNA were
selected by blasticidin. (A-B) Flow cytometric results showed that the percentages of apoptotic cells in both HPSE-miRNA groups were not different
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PLoS ONE | www.plosone.org 6 June 2012 | Volume 7 | Issue 6 | e38659locations and requires a critical event for the ability of tumor cells
to degrade and penetrate the ECM and BM [23]. HPSE is an
endoglycosidase involved in HPSGs cleavage, a key component of
the ECM, BM, and cell surface proteoglycans, leading to ECM
remodeling, which may facilitate the cellular invasiveness associ-
ated with cancer metastasis [24–28]. During the past decade,
many clinical data have revealed that the overexpression of HPSE
correlates with reduced postoperative survival and poorer prog-
from those in the parental cells or the Neg-miRNA group (P.0.05). (C) MTT assay showed that HPSE miRNA attenuated the cellular viability of A375
cells at both 24 hours and 48 hours, compared to the parental cells or the Neg-miRNA transfected cells. (D) Cellular proliferation assay using cell
counts showed that HPSE miRNA could also inhibit cellular proliferation of A375 cells at 48, 72 and 96 hours, compared to the parental cells or the
Neg-miRNA transfected cells. (E) Cell-Matrigel adhesion assay. The adhesive ability of A375 cells transfected with HPSE miRNAs was obviously
inhibited compared to control groups. (F) Diagram of migrative cells or invasive cells, as determined by the transwell migration assay or the Matrigel-
invasion assay. The migrative or invasive number of A375 cells transfected with HPSE miRNAs was much less than that of either control group. (G)
Representative images of migrative cells in the HPSE miRNAs groups or control groups in the transwell migration assay (H&E staining, magnification
of 10610). (H) Representative images of invasive cells in the HPSE miRNAs groups or control groups in Matrigel invasion assay(H&E staining,
magnification of 10610). (
{P,0.05, compared with the parental cells; *P,0.05, compared with the Neg-miRNA transfected cells).
doi:10.1371/journal.pone.0038659.g002
Figure 3. HPSE miRNAs inhibited expression of IL8 and CXCL1 and its probable mechanism. (A) Differentially expressed chemokine genes
in the HPSE-miRNA1 and HPSE-miRNA2 groups compared to the Neg-miRNA group (log2 ratio$1 or log2 ratio#21 and P,0.05). (B) Pathways
including chemokines activity modulated by HPSE-miRNA1 or HPSE-miRNA2 were confirmed to be significant by gene-set enrichment analysis
(P,0.05). (C) Both the mRNA and protein levels of IL8 and CXCL1 in HPSE miRNA transfected A375 cells were decreased compared to either control
group. (
{P,0.001, compared with the parental cells; *P,0.001, compared with the Neg-miRNA transfected cells). (D) Attenuation of the HPSE-
induced phosphorylation of MAPKs by HPSE miRNA. Phosphorylation of MAPK p38 (second and third panel), JNK/SAPK (fourth and fifth panel), and
ERK1/2 (sixth and seventh panel) was monitored by western blotting.
doi:10.1371/journal.pone.0038659.g003
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patients [24–28]. Similarly, HPSE up-regulation also correlates
with increased lymph node and distant metastasis [24,27,29] and
with microvessel density [24,29,30], providing strong clinical
support for the prometastatic and proangiogenic features of HPSE
and positioning HPSE as a potentially new and promising drug
target.
Due to potential nonspecific activity and significant toxicity of
HPSE inhibitors, RNAi targeting HPSE (HPSE-siRNA or HPSE-
shRNA) has been developed. This HPSE RNAi leads to slow
growth, reduced clonogenic capacity, and invasive potential of
aggressive tumor cell lines [31,32]. Recent reports demonstrated
that embedding a shRNA in the context of a naturally occurring
Pol II-driven miRNA transcript increases the flexibility of RNAi
allowing for conditional and cell type-specific expression [17,18].
Additionally, such miRNA-based RNAi systems displayed very
efficient knockdown of gene expression, even at a single copy
[13,14]. Furthermore, such an approach could alleviate the
toxicity resulting from interference with the endogenous miRNA
pathway or induction of the interferon response [33,34]. In the
present study, we utilized the BLOCK-iT
TM Pol II miR RNAi
expression vectors containing the human cytomegalovirus imme-
diate early promoter to allow high-level, constitutive miRNA
expression in mammalian cells. The engineered pre-miRNA
sequence structure is based on the murine miR-155 sequence
[35], which is one of the most characterized and commonly used
pre-miRNA backbones [36]. We designed three different sequenc-
es targeting the HPSE gene, and the artificial HPSE miRNA was
cloned and expressed. The silencing effect of the artificial miRNA,
verified by real-time PCR and western blotting, showed that both
the HPSE protein and mRNA were down-regulated in HPSE
miRNA transfected A375 cells, especially in the HPSE-miRNA1
Figure 4. The effect of HPSE miRNA on the in vivo lung metastasis of A375 cells. Cells (2610
6) from the parental cells, Neg-miRNA or HPSE-
miRNA2 transfected cells were injected into the tail veins of nude mice. (A-B) Xenograft mice were weight once a week for 6 weeks, and photos were
taken at the end of the experiment on day 42, as shown in A. A weight increase was noted in the HPSE-miRNA2 group, compared to the control
groups. (C) Representative lung tissue sections from each group (H&E staining, magnification of640,6100 and6400, respectively). (D) The number
of lung metastases in HPSE-miRNA2 mice was decreased compared to that of mock control and Neg-miRNA control groups. (
{P,0.05, compared with
the parental cells; *P,0.05, compared with the Neg-miRNA transfected cells).
doi:10.1371/journal.pone.0038659.g004
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indicated that the artificial miRNAs could reduce the cellular
concentration of their target mRNA and protein level [37,38]. It
was interesting that in our miRNA rescue experiments, only the
mutated HPSE cDNA could completely restore the HPSE
expression in HPSE-miRNA2 transfected cells at the transcrip-
tional and translational levels (Figure 5B and C), consistent with
the results from the Qin LX group [20]. The Qin LX group also
constructed artificial miRNAs against osteopontin (OPN) and
selected the OPNi-3 as the most effective miRNA. However,
OPNi-3M, a control pre-miRNA with two mismatch mutations,
did not display translational repression on OPN. The results from
our group as well as other groups have indicated that artificial
miRNAs may commonly encode a perfectly complementary guide
strand that causes gene inhibition via mRNA cleavage [20,36],
unlike endogenous miRNAs with complete or partial complemen-
tarity to the target gene. miR-1258, an endogenous miRNA, was
recently reported to suppress breast cancer brain metastasis by
targeting HPSE. Decreased cell invasion and numbers of brain
metastasis by treatment with miR-1258 were just partly reversed
by employing an expression vector containing human HPSE [39].
To our knowledge, the data described here represents the first
successful application of artificial miRNA-mediated gene silencing
to effectively reduce the levels of HPSE.
The accumulated evidence has revealed that HSPGs inhibit
cellular invasion by promoting tight cell-cell and cell-ECM
interactions and by maintaining the structural integrity and self-
assembly of the ECM [40,41]. Therefore, the excessive
expression of HPSE therefore may accelerate tumor cell
dissemination, enabling the penetration of cells through the
ECM barrier and improving tumor cell adhesion to endothelial
cells and the subendothelial ECM by cleaving HSPGs [42,43]. In
view of the possible influence of cellular proliferation and
viability on the migration or invasion of cells, we selected 24
hours as the observation point; at this time point, the cells
number did not differ significantly amongst the groups, even
though cellular viability between HPSE miRNA groups and
control groups differed. Expectedly, in the present study, HPSE
miRNA was able to abolish the invasive properties of melanoma
cells in vitro, including adhesion, migration, and invasion
(Figure 2E–H), which was consistent with previous studies
[31,32]. Xenograft models further confirmed that the down-
Figure 5. Restoration of HPSE functionality by HPSE RNAi rescue. (A) The sequencing results of the wild type and multisite mutant HPSE
cDNA. Three nucleotide substitutions were introduced into the HPSE-miRNA2 hybridizing sequence (59-CCTTTGCAGCTGGCTTTATGT-39), which was
verified by sequencing. (B-D) The levels of both HPSE mRNA and protein were restored in cells of the HPSE-miRNA2 group transfected with mutant
HPSE cDNA, similar to those of Neg-miRNA cells transfected with the wild type or mutant HPSE cDNA. Furthermore, mutant cDNA transfection for
miRNA rescue also increased IL8 and CXCL1 mRNA and protein levels. However, in HPSE-miRNA1 stably transfected cells, neither the wild type HPSE
cDNA nor the mutant HPSE cDNA could restore the expressions of HPSE, IL8 and CXCL1.( * P,0.05 compared with the respective non-cotransfected
cells). (E) Restoration of the HPSE-induced phosphorylation of MAPKs in the cells of the HPSE-miRNA2 group by mutant HPSE cDNA. Phosphorylation
of MAPK p38 (first and second panel), JNK/SAPK (third and fourth panel), and ERK1/2 (fifth and sixth panel) was monitored by western blotting.
doi:10.1371/journal.pone.0038659.g005
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inhibition of in vivo lung metastasis of A375 cells (Figure 4C and
D). The inhibitory effect of HPSE miRNA on the metastasis of
melanoma in vitro and in vivo may be partly correlated with its
suppression on cellular viability and proliferation, as well as the
known important role of HPSE on the metastasis of melanoma.
To identify whether the silencing of unpredicted genes was due
to off-target effects of RNAi or due to a secondary effect of the
knock-down of the target gene, global gene expression patterns
were analyzed [44,45]. Our gene microarray results showed that
205 overlapping genes were up- or down-regulated by both HPSE
miRNAs that targeted different sequences of the HPSE mRNA. It
was worth noting that chemokines of IL8, CXCL1, CCL2, and
CCL11 were found to be down-regulated in both HPSE miRNA
groups, the former two chemokine levels were confirmed by real-
time PCR and ELISA assay (Figure 3C). Chemokines are secreted,
low-molecular-weight chemotactic proteins that regulate the
trafficking of leukocytes, including neutrophils, macrophages,
and lymphocytes, to inflammatory sites. The metastasis of tumor
cells has also been revealed to adopt a chemokine-mediated
homing mechanism, similar to that of leukocyte trafficking.
Previous studies reported that melanoma cells express high levels
of IL8 and CXCL1 and their receptors CXCR1/2 and that IL8/
CXCL1 signaling directly promotes cell migration of tumor cells,
which may be relevant to tumor invasion and metastasis [46,47].
Furthermore, melanoma cells produced and secreted high levels of
IL8, which attracts neutrophils and increases b-2 integrin
expression on their surface, which then interacts with intercellular
adhesion molecule-1 on melanoma cells to promote anchoring to
the vascular endothelium [48].
To date, the mechanism by which HPSE facilitates the
expression of chemokines is thought to involve the release of
ECM-resident chemokines [50]. HPSG serves as a storage depot
for various members of the heparin-binding family of growth
factors, cytokines, and chemokines [2,49], and the cleavage of
HPGS by HPSE ultimately releases these proteins and converts
them into bioactive mediators. However, the mechanism by which
IL8 or CXCL1 gene expression is regulated by HPSE at the
transcriptional level remains unknown. The MAPK pathway is
constitutively activated in most melanomas and plays a major role
in mediating the survival and progression of melanoma [50,51]. In
addition, p38 MAPK [52], JNK [53], and ERK [54] are involved
in the regulation of IL8 expression in a variety of cell types. HPSE
could promote phosphorylation of signaling molecules such as Akt
and Src, facilitating gene transcription and phosphorylation of
selected Src substrates [43,55], whereas HPSE silencing was
accompanied by reduced EGFR and Src phosphorylation levels
[56]. Similarly, p38 MAPK activation may also be mediated by
HPSE, resulting in the enhanced transcription of genes such as
vascular endothelial growth factor [51], tissue factor (TF) [57], and
cyclooxygenase-2 [58]. Herein, we provided evidence that the
knockdown of HPSE with a HPSE miRNA reduced IL8 and
CXCL1 in melanoma cells at both the transcriptional and
translational levels (Figure 3C). In addition to release by HPSE,
the gene expression of IL8 and CXCL1 may be mediated by the
HPSE-induced phosphorylation of the p38 MAPK, JNK, and
ERK pathway (Figure 3D). In RNAi rescue experiments to
corroborate the specificity of the HPSE miRNA, the expression of
IL8 and CXCL1 and the phosphorylation of MAPK were
upregulated concordantly when the miRNA knockdown was
rescued by an incompatible, mutated miRNA HPSE cDNA
(Figure 5D and E). Thus, we inferred that the HPSE miRNA
could block the expression of IL8 and CXCL1, thus impairing the
effect of IL8 and CXCL1 on the migration and invasion of tumor
cells (Figure S5).
In conclusion, our data suggests that artificial miRNA driven by
the Pol II cytomegalovirus promoter may inhibit the expression of
the HPSE protein and mRNA effectively, resulting in decreased
invasion properties of melanoma cells in vitro and in vivo. Moreover,
inhibition of HPSE by miRNA was able to down-regulate IL8 and
CXCL1 not only at the translational level, but also at the
transcriptional level by the attenuation of MAPK phosphorylation,
indicating that miRNAs could be useful tools to study gene
function. However, there are still many problems that need to be
addressed, including i) whether shRNAs targeting HPSE, based on
an miRNA scaffold, are more efficient and safer compared with
HPSE-shRNAs, siRNAs or inhibitors, ii) whether such HPSE
miRNAs can be expressed in a conditional or tissue-specific
manner in vitro or in vivo by the introduction of tissue-specific
promoters, iii) whether there are suitable systems, such as
optimized viral vectors or modified liposomes, to deliver the
artificial miRNAs in vivo.
Supporting Information
Figure S1 The process of multisite mutagenesis of HPSE
cDNA. The following reactions were set up to produce mutated
HPSE mRNA that is not degraded by HPSE-miRNA2. (A) Three
nucleotide substitutions were introduced into the HPSE-miRNA2
hybridizing sequence (59-CCTTTGCAGCTGGCTTTATGT-39),
whichretainedtheaminoacididentityofthewild-typeprotein.(B-C)
The PCR reaction system, as shown in B, was set up to produce
mutated HPSE cDNA, under the PCR condition shown in C. (D)
The PCR mutagenesis reaction products were digested with 1.0 mL
D p nIa t3 7 uC for 4 hours and were subsequently used for the
transformation of TOP10 bacteria transformation. (E) DNA from
positive colonies was isolated using a purification kit, digested by
EcoRI and XhoI restriction enzymes and verified for correctness by
electrophoresis,and sequenced (showninFigure 5A). These mutated
HPSE cDNAs were used for co-transfecting Neg-miRNA, HPSE-
miRNA1 and HPSE-miRNA2 transfected cells for RNAi rescue.
(TIF)
Figure S2 The correctness of HPSE-miRNA1, HPSE-
miRNA2 and HPSE-miRNA3 were confirmed by se-
quencing.
(TIF)
Figure S3 HPSE miRNA down-regulated the expression
of HPSE and inhibited adhesion, migration and invasion
of HeLa cells. (A) Quantitative real-time PCR results showed
that the expression of HPSE mRNA in HeLa cells transfected with
HPSE-miRNA1 was down-regulated compared to the parental
cells and the Neg-miRNA transfected cells. (B) Representative
blots were shown from three independent experiments with
identical results. The expression of the HPSE protein of HeLa cells
transfected with HPSE-miRNA1 was down-regulated compared
to the parental cells and the Neg-miRNA group. (C) Cell-Matrigel
adhesion assay. The adhesive ability of HeLa cells transfected with
HPSE-miRNA1 was obviously inhibited compared to the parental
cells and the Neg-miRNA group. (D) Representative images of
invasive cells with HPSE-miRNA1, Neg-miRNA and parental
cells from the Matrigel invasion assay (H&E staining, magnifica-
tion of 40610). (E) Representatives of migration cells from
different groups in wound healing assays. The parental HeLa
cells, and cells transfected with the Neg-miRNA or the HPSE-
miRNA1, were seeded in 24-well plates at 2.5610
5 per well in a
growth medium to form a confluent monolayer. Then a single
HPSE-miRNA Inhibits Invasion, Correlates with MAPK
PLoS ONE | www.plosone.org 10 June 2012 | Volume 7 | Issue 6 | e38659scratch wound was created using a micropipette tip and cells were
washed with phosphate-buffered saline to remove cell debris,
supplemented with assay medium without serum. The images
were captured with a microscope using a 10 6objective at 0 and
48 hours post-wounding. (F) Diagram of migrative cells or invasive
cells as determined by the would healing assay or the Matrigel
invasion assay. The number of migrative and invasive number of
HeLa cells transfected with HPSE-miRNA1 was much less than
that of either control group. (
{P,0.05 compared with the parental
cells; *P,0.05 compared with the Neg-miRNA transfected cells).
(TIF)
Figure S4 Differential gene expression caused by the
knockdown of HPSE and its related functional pathway.
(A) Differential gene expression between the Neg-miRNA and the
HPSE-miRNA1 or HPSE-miRNA2 transfected A375 cells by
gene microarray analysis using Phalanx Human OneArray
TM
slides. (B) 205 overlapping genes were analyzed for functional
annotation by DAVID.
(TIF)
Figure S5 Schematic representation of the hypothetical
molecular mechanisms, by which the HPSE miRNA
regulates the expression of IL8 and CXCL1 and partic-
ipates in the inhibition of melanoma migration and
invasion. (A) Schematic diagram of the HPSE-induced IL8/
CXCL1/MAPK pathway. (B) The HPSE miRNA blocked the
expression of IL8 and CXCL1 and participated in the inhibition of
melanoma migration and invasion. (C) Schematic drawing of
distant metastasis of melanoma induced by IL8 or CXCL1.
(TIF)
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